Skip to main content
15/11/2023

Two VHIR and Cemcat researchers among the most cited in 2023 according to Clarivate

Laboratori

Research lab

15/11/2023

The list identifies the most influential experts, who are among the 1% most cited in their speciality in several areas of knowledge.

On Wednesday 15 November, Clarivate Analytics published the list of the most cited scientists in 2023. This is one of the most prestigious rankings among the international academic and scientific community that once again this year has the presence of professionals from the Vall d'Hebron Research Institute (VHIR) and the Multiple Sclerosis Centre of Catalonia (Cemcat).

In the category of Neurosciences and Behaviour, Dr. Xavier Montalban, head of the Neurology Service at Vall d'Hebron University Hospital, head of the Clinical Neuroimmunology research group at VHIR and director of Cemcat, and Dr. Mar Tintoré, clinical head of the Neurology Service at Vall d'Hebron University Hospital, principal investigator at the Clinical Neuroimmunology research group at VHIR and head of healthcare at Cemcat.

Clarivate list of most highly cited researchers

Determined by the Clarivate team, the list includes selected researchers who have written multiple highly cited articles that rank in the top 1% of the most cited articles per field and per year in Web of Science over the last decade. This is not the only selection indicator. A preliminary list based on citation activity is then refined through qualitative analysis and expert judgement.

This year's Highly Cited Researcher designations have been awarded to 7,125 individuals. This small fraction of the research population contributes significantly to pushing the frontiers of knowledge and achieving innovative solutions to make the world healthier, more sustainable and safer.

The full list of highly cited researchers in 2023 can be found here.

Related news

A study conducted at the Catalan Multiple Sclerosis Centre (Cemcat) shows that the lack of a reduction in neurofilament light chain during the first year of treatment is associated with a higher risk of subsequent disease activity.

The project’s 4th annual meeting was recently held as part of the Fortalece–Salud programme of the Carlos III Health Institute.

An international study led by researchers from Vall d’Hebron shows that simple tests that patients can perform themselves help detect changes in disability that may occur even in the absence of disease relapses.

Related professionals

Montserrat Romero Reinaldos

Montserrat Romero Reinaldos

Research technician
Clinical Neuroimmunology
Read more
Carmen Tur Gomez

Carmen Tur Gomez

Main researcher
Clinical Neuroimmunology
Read more
Gaizka Loyola Sanmillan

Gaizka Loyola Sanmillan

Research technician
Clinical Neuroimmunology
Read more
Agustin Pappolla

Agustin Pappolla

Predoctoral researcher
Clinical Neuroimmunology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.